CYLD inhibits tumorigenesis and metastasis by blocking JNK/AP1 signaling at multiple levels

Cancer Prevention Research

Volumn 4, Issue 6, 2011, Pages 851-859

  De Marval, Paula Miliani ^a   Lutfeali, Shazia ^a   Jin, Jane Y ^a   Leshin, Benjamin ^a   Angelica Selim, M ^a   Zhang, Jennifer Y ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN C FOS; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TRANSCRIPTION FACTOR AP 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL GROWTH; CELL MIGRATION; CONTROLLED STUDY; CYLD GENE; ENZYME ACTIVATION; GENE; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC ANALYSIS; HUMAN; LYMPH NODE METASTASIS; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; UPREGULATION;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CARCINOGENS; CARCINOMA, SQUAMOUS CELL; CYSTEINE ENDOPEPTIDASES; DISEASE PROGRESSION; EPIDERMIS; HUMANS; HYPERPLASIA; IMMUNOBLOTTING; IMMUNOPRECIPITATION; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LYMPHATIC METASTASIS; MICE; MICE, TRANSGENIC; MUTATION; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; SKIN NEOPLASMS; TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTION FACTOR AP-1; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; UBIQUITINATION;

EID: 79957845596     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0360     Document Type: Article

References (44)

1. Regamey A, Hohl D, Liu JW, Roger T, Kogerman P, Toftgard R, et al. The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor. J Exp Med 2003;198:1959-64. (Pubitemid 38032127)
2. Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 2003;424:797-801. (Pubitemid 37021711)
3. Kovalenko A, Chable-Bessia C, Cantarella G, Israël A, Wallach D, Courtois G, et al. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003;424:801-5. (Pubitemid 37021712)
4. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G, et al. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 2003;424:793-6. (Pubitemid 37021710)
5. Reiley W, Zhang M, Sun SC. Negative regulation of JNK signaling by the tumor suppressor CYLD. J Biol Chem 2004;279:55161-7. (Pubitemid 40066510)
6. Stegmeier F, Sowa ME, Nalepa G, Gygi SP, Harper JW, Elledge SJ, et al. The tumor suppressor CYLD regulates entry into mitosis. Proc Natl Acad Sci U S A 2007;104:8869-74. (Pubitemid 47175403)
7. Reiley WW, Zhang M, Jin W, Losiewicz M, Donohue KB, Norbury CC, et al. Regulation of T cell development by the deubiquitinating enzyme CYLD. Nat Immunol 2006;7:411-7.
8. Reiley WW, Jin W, Lee AJ, Wright A, Wu X, Tewalt EF, et al. Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J Exp Med 2007204:1475-85.
9. Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R, et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet 2000;25:160-5. (Pubitemid 30394985)
10. Blake PW, Toro JR. Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in cell signaling. Hum Mutat 2009;30:1025-36.
11. Leonard N, Chaggar R, Jones C, Takahashi M, Nikitopoulou A, Lakhani SR. Loss of heterozygosity at cylindromatosis gene locus, CYLD, in sporadic skin adnexal tumours. J Clin Pathol 2001;54:689-92. (Pubitemid 32835416)
12. Takahashi M, Rapley E, Biggs PJ, Lakhani SR, Cooke D, Hansen J, et al. Linkage and LOH studies in 19 cylindromatosis families show no evidence of genetic heterogeneity and refine the CYLD locus on chromosome 16q12-q13. Hum Genet 2000;106:58-65. (Pubitemid 30156395)
13. Thomson SA, Rasmussen SA, Zhang J, Wallace MR. A new hereditary cylindromatosis family associated with CYLD1 on chromosome 16. Hum Genet 1999;105:171-3. (Pubitemid 29396984)
14. Biggs PJ, Chapman P, Lakhani SR, Burn J, Stratton MR. The cylindromatosis gene (cyld1) on chromosome 16q may be the only tumour suppressor gene involved in the development of cylindromas. Oncogene 1996;12:1375-7. (Pubitemid 26127270)
15. Gao J, Huo L, Sun X, Liu M, Li D, Dong JT, et al. The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration. J Biol Chem 2008;283:8802-9.
16. Massoumi R, Kuphal S, Hellerbrand C, Haas B, Wild P, Spruss T, et al. Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med 2009;206:221-32.
17. Hutti JE, Shen RR, Abbott DW, Zhou AY, Sprott KM, Asara JM, et al. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol Cell 2009;34:461-72.
18. Wang L, Baiocchi RA, Pal S, Mosialos G, Caligiuri M, Sif S. The BRG1- and hBRM-associated factor BAF57 induces apoptosis by stimulating expression of the cylindromatosis tumor suppressor gene. Mol Cell Biol 2005;25:7953-65. (Pubitemid 41262990)
19. Hellerbrand C, Bumes E, Bataille F, Dietmaier W, Massoumi R, Bosserhoff AK. Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis 2007;28:21-7. (Pubitemid 44942623)
20. Ströbel P, Zettl A, Ren Z, Starostik P, Riedmiller H, Störkel S, et al. Spiradenocylindroma of the kidney: clinical and genetic findings suggesting a role of somatic mutation of the CYLD1 gene in the oncogenesis of an unusual renal neoplasm. Am J Surg Pathol 2002;26:119-24. (Pubitemid 34020000)
21. Hirai Y, Kawamata Y, Takeshima N, Furuta R, Kitagawa T, Kawaguchi T, et al. Conventional and array-based comparative genomic hybridization analyses of novel cell lines harboring HPV18 from glassy cell carcinoma of the uterine cervix. Int J Oncol 2004;24:977-86.
22. Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 2006;125:665-77.
23. Oosterkamp HM, Neering H, Nijman SM, Dirac AM, Mooi WJ, Bernards R, et al. An evaluation of the efficacy of topical application of salicylic acid for the treatment of familial cylindromatosis. Br J Dermatol 2006;155:182-5. (Pubitemid 43876412)
24. Dajee M, Lazarov M, Zhang JY, Cai T, Green CL, Russell AJ, et al. NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 2003;421:639-43. (Pubitemid 36227672)
25. Ke H, Harris R, Coloff JL, Jin JY, Leshin B, Miliani de Marval P, et al. The c-Jun NH2-terminal kinase 2 plays a dominant role in human epidermal neoplasia. Cancer Res 2010;70:3080-8.
26. van Hogerlinden M, Rozell BL, Ahrlund-Richter L, Toftgard R. Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-kappaB signaling. Cancer Res 1999;59:3299-303. (Pubitemid 29334479)
27. Vassar R, Rosenberg M, Ross S, Tyner A, Fuchs E. Tissue-specific and differentiation-specific expression of a human K14 keratin gene in transgenic mice. Proc Natl Acad Sci U S A 1989;86:1563-7. (Pubitemid 19078943)
28. Robbins PB, Lin Q, Goodnough JB, Tian H, Chen X, Khavari PA. In vivo restoration of laminin 5 beta 3 expression and function in junctional epidermolysis bullosa. Proc Natl Acad Sci U S A 2001;98:5193-8.
29. Tang ED, Wang CY, Xiong Y, Guan KL. A role for NF-kappaB essential modifier/IkappaB kinase-gamma (NEMO/IKKgamma) ubiquitination in the activation of the IkappaB kinase complex by tumor necrosis factor-alpha. J Biol Chem 2003;278:37297-305. (Pubitemid 37175246)
30. Robles AI, Rodriguez-Puebla ML, Glick AB, Trempus C, Hansen L, Sicinski P, et al. Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev 1998;12:2469-74. (Pubitemid 28406950)
31. Zhang JY, Adams AE, Ridky TW, Tao S, Khavari PA. Tumor necrosis factor receptor 1/c-Jun-NH2-kinase signaling promotes human neoplasia. Cancer Res 2007;67:3827-34. (Pubitemid 46762170)
32. Lichti U, Anders J, Yuspa SH. Isolation and short-term culture of primary keratinocytes, hair follicle populations and dermal cells from newborn mice and keratinocytes from adult mice for in vitro analysis and for grafting to immunodeficient mice. Nat Protoc 2008;3:799-810. (Pubitemid 351639024)
33. Gilmore TD. The Rel/NF-kappaB signal transduction pathway introduction. Oncogene 1999;18:6842-4.
34. Ke H, Harris R, Coloff JL, Jin JY, Leshin B, Miliani de Marval P, et al. The c-Jun NH2-terminal kinase 2 plays a dominant role in human epidermal neoplasia. Cancer Res 2010;70:3080-8.
35. Brown PH, Alani R, Preis LH, Szabo E, Birrer MJ. Suppression of oncogene-induced transformation by a deletion mutant of c-jun. Oncogene 1993;8:877-86. (Pubitemid 23087418)
36. Chinenov Y, Kerppola TK. Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene 2001;20:2438-52. (Pubitemid 32531301)
37. Rajan N, Langtry JA, Ashworth A, Roberts C, Chapman P, Burn J, et al. Tumor mapping in 2 large multigenerational families with CYLD mutations: implications for disease management and tumor induction. Arch Dermatol 2009;145:1277-84.
38. De Francesco V, Frattasio A, Pillon B, Stinco G, Scott CA, Trotter D, et al. Carcinosarcoma arising in a patient with multiple cylindromas. Am J Dermatopathol 2005;27:21-6. (Pubitemid 40189019)
39. Wannenmacher M, Schutz J. [Therapeutic consequences from the slow growth of cylindroma and their metastasis]. Stoma 1971;24:197-204.
40. Fukai K, Aida K, Aoki K. [2 autopsy cases of so-called cylindroma with widespread metastasis]. Kita Kanto Igaku 1963;13:93-106.
41. Kazakov DV, Benkova K, Michal M, Vanecek T, Kacerovska D, Skalova A, et al. Skin type spiradenoma of the parotid gland with malignant transformation Report of a case with analysis of the CYLD gene. Hum Pathol 2009;40:1499-503.
42. Alameda JP, Moreno-Maldonado R, Navarro M, Bravo A, Ramírez A, Page A, et al. An inactivating CYLD mutation promotes skin tumor progression by conferring enhanced proliferative, survival and angiogenic properties to epidermal cancer cells. Oncogene 2010;29:6522-32.
43. Gao J, Sun L, Huo L, Liu M, Li D, Zhou J. CYLD regulates angiogenesis by mediating vascular endothelial cell migration. Blood 2010;115:4130-7.
44. Zhang JY, Green CL, Tao S, Khavari PA. NF-kappaB RelA opposes epidermal proliferation driven by TNFR1 and JNK. Genes Dev 2004;18:17-22. (Pubitemid 38090684)